CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia

by | Oct 1, 2025 | Clinical Trials | 0 comments

​ Conditions: AML – Acute Myeloid Leukemia

Interventions: Biological: CD123+CLL-1 dual-target CAR-T cells sequential infusion CD7 CAR-T cells and bridging to allogeneic

Sponsors: Institute of Hematology & Blood Diseases Hospital, China

Not yet recruiting Conditions: AML – Acute Myeloid Leukemia
Interventions: Biological: CD123+CLL-1 dual-target CAR-T cells sequential infusion CD7 CAR-T cells and bridging to allogeneic
Sponsors: Institute of Hematology & Blood Diseases Hospital, China
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *